Richard M Craig

6632961, Oct 14, 2003

May 21, 1999

09/316856

Megumi Kawai - Libertyville IL
Jack Henkin - Highland Park IL
George S. Sheppard - Wilmette IL
Richard A. Craig - Racine WI

Abbott Laboratories - Abbott Park IL

C07K 6500

562405, 514 19, 562553, 562562

Compounds having Formula I or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

6849757, Feb 1, 2005

Jul 10, 2003

10/616628

Megumi Kawai - Libertyville IL, US
Jack Henkin - Highland Park IL, US
George S. Sheppard - Wilmette IL, US
Richard A. Craig - Racine WI, US

Abbott Laboratories - Abbott Park IL

C07C 6976

560102, 560 41, 562492, 564169

Compounds having Formula I or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

7030262, Apr 18, 2006

Aug 6, 2003

10/635342

Nwe Y. BaMaung - Niles IL, US
Richard A. Craig - Racine WI, US
Jack Henkin - Highland Park IL, US
Megumi Kawai - Libertyville IL, US
Xenia B. Searle - Grayslake IL, US
George S. Sheppard - Wilmette IL, US
Jieyi Wang - Lake Bluff IL, US

Abbott Laboratories - Abbott Park IL

C07C 331/00

560 19, 560155, 562433, 562553

Compounds having the formula are useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

7167490, Jan 23, 2007

Mar 8, 2004

10/795925

David G. Mehuys - Sunnyvale CA, US
Richard R. Craig - Palo Alto CA, US
Jay A. Skidmore - San Jose CA, US
Vincent V. Wong - San Jose CA, US

JDS Uniphase Corporation - Milpitas CA

H01S 3/10

372 23, 372102, 372 96

An optical fiber laser has an output that is stabilized to adapt to changes in laser operating temperature. At the output of the laser a plurality of wavelength-selective stabilizing reflectors is provided, each having a reflectivity profile with a different center wavelength. The reflectors, typically Bragg gratings, have a relative degree of reflectivity and relative wavelength separation that results in the output power of the laser being at one or more of the reflector center wavelengths throughout the temperature change. Thus, as a temperature shift causes the wavelength of the optical energy generated in the laser gain medium to change, the grating-stabilized output of the laser shifts between one locked wavelength and another. However, the output remains stable over the extended wavelength range provided by the multiple reflectors. Such a laser is particularly useful in an amplifier system in which the laser is used as an optical pump source.

20020091148, Jul 11, 2002

Sep 14, 2001

09/952603

Nwe BaMaung - Niles IL, US
Richard Craig - Racine WI, US
Megumi Kawai - Libertyville IL, US
Jieyi Wang - Lake Bluff IL, US
Yujia Dai - Gurnee IL, US
Yan Guo - Gurnee IL, US
George Sheppard - Wilmette IL, US
Mary Verzal - Kenosha WI, US
Anil Vasudevan - Gurnee IL, US
Michael Michaelides - Libertyville IL, US

A61K031/404

514/414000, 514/419000

3-Substituted indole carbohydrazides having the formula are useful for inhibiting angiogenesis and cell proliferation. Also disclosed are compositions which inhibit angiogenesis and cell proliferation and methods of inhibiting angiogenesis and cancer in a mammal.

50330543, Jul 16, 1991

Aug 17, 1990

7/568942

Donald R. Scifres - San Jose CA
Richard R. Craig - Palo Alto CA
Robert G. Waarts - Palo Alto CA

Spectra Diode Laboratories, Inc. - San Jose CA

H01S 305

372 50

A laser having a phase conjugating reflector positioned with a resonant cavity of a laser configuration capable of multimode operation. The resonant cavity or other means associated with the laser configuration selects the preferred mode at threshold. The phase conjugating material builds up reflectivity as the light intensity is increased above threshold power levels to maintain the selected mode to high power levels. One embodiment has an external Talbot cavity with a first mirror in a Talbot plane of a multi-emitter laser array and with the phase conjugating material at a sub-Talbot plane. Another embodiment has an external GRIN lens cavity with a far field apertured stripe mirror for threshold mode selection. The phase conjugator is placed at a high light intensity position within the cavity such as adjacent to the stripe mirror or adjacent to the laser array. The laser source may be a linear laser diode array or a 2-D surface emitting laser array.

57565317, May 26, 1998

Apr 30, 1996

8/640271

Clint D. W. Brooks - Libertyville IL
Richard A. Craig - Racine WI
David E. Gunn - Hamden CT
Jimmie L. Moore - Gurnee IL
Andrew O. Stewart - Libertyville IL

Abbott Laboratories - Abbott Park IL

C07D20912
C07D20914
A61K 3140
A61K 31405

514408

The present invention provides a class of substituted indole and indene iminoxy derivatives of the formula ##STR1## which inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states.

55062610, Apr 9, 1996

May 9, 1994

8/239648

Dee W. Brooks - Libertyville IL
Andrew O. Stewart - Libertyville IL
Richard A. Craig - Racine WI

Abbott Laboratories - Abbott Park IL

C07D33332
C07D33334
A61K 3138
A61K 31385

514438

Compounds of the structure ##STR1## wherein Z is selected from optionally substituted thienyl, thiazolyl, oxazolyl and furyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.